Doron Birger is a chairman and director of several public and privet owned companies in the fields of Medical Device, Internet and Digital Printing. Mr. Birger served as the CEO of Elron Electronic Industries, Ltd., (Nasdaq ELRNF and TASE ). In the medical device arena, Mr. Birger was chairman and director of Given Imaging (Nasdaq :GIVN and TASE) until it was sold to Covidian (today Medtronic), and Medingo until it was sold to Roche, as well as a director or chairman of many privately held companies in the Elron group in the fields of medical devices, semiconductors and communication. Mr. Birger holds a B.A. and an M.A. in economics from the Hebrew University, Jerusalem.
Eyal is currently serves as a CEO in the company. As of 2004 the Chief Executive Officer of SHL Telemedizin in Germany. Eyal introduced the telemedicine concept to the German market, including remote monitoring of patients suffering from chronic disease like heart insufficiency, diabetes and lung disease. The introduction of new concepts requires close work with the different players in the German healthcare market as well as the German insurance companies. While establishing the company and penetrating the German market Eyal lived most of the years in Germany and therefore understands the German culture and speaks fluent German. Prior to SHL in Germany Eyal worked in the telecommunication arena with Comverse, bringing significant success in penetrating green field large customers in Europe and east Europe, Africa and far east Asia . Eyal served for eight years in the Israeli Air Force, reaching the rank of Major. He holds a BA in Economics and Management from Tel Aviv University
Prior to joining Insuline Medical Ron was Vice President and CEO of Teva Israel, Israel’s leading pharmaceutical company with annual sales of over $650M. During his 21 years at Teva and its subsidiaries, he held key positions as Vice President of Russia & Regional Markets International Group at 2008-2009, where he was responsible for the integration of Barr/Pliva into Teva and establishing the new region. From 2007-2008 he was Vice President of Commercial Affairs, International Group, where he led the Global SCM, Product Portfolio, Regulatory Affairs, Marketing and Business Development. In addition, he held several management positions, including Manger of Global Distribution Projects Team, Manger of BOOTS Unit In Israel and Sales & Marketing Manager in the Palestinian Authority. Until 2012 Ron served as Director of the Board at OXAR and Argon Works Ltd., the largest manufacturer and supplier of Industrial Gases in Israel. Prior to that, he was Active Chairman of the Board at Sicor Europe SA. Ron has an M.B.A, from the University of Tel-Aviv where he majored in information systems with secondary stream in Technology Management and Operational Systems.
An associate professor and vice-dean of the Faculty of Biotechnology and Food Engineering at the Technion Haifa Israel. Marcelle Machluf holed a PhD degree from the Faculty of Chemical Engineering the unit of Biotechnology, Ben Gurion University Bear Sheva, in Liposomes and polymer delivery for vaccines development. Prof Machluf had a post-doctoral fellowship of five years experience in drug delivery, gene therapy and tissue engineering in Harvard Medical School, Boston MA, US. Professor Machluf laboratory focuses in developing scaffolds for tissue engineering of the heart, blood vessels and pancreas. Her group also develops and engineers drug and gene delivery systems for cancer therapy. Professor Machluf has published more then 40 papers and chapters in books and has 7 patent applications in national phase
The General Manager (since April 2011) of Teledata Networks Ltd - a high tech company which is a leading global provider of innovative Access Network solutions and products for telecom service providers.Prior to that, he served as CFO&VP Operations at Teledata since 2006. Between 1998– 2004, he worked in New York, as CFO of Tadiran Electronics Inc and later on as the President of Elisra Inc.Previously he was the Corporate Director of Finance of Tadiran Ltd. He holds an MBA degree from the Hebrew University in Jerusalem.
Jacob Harel is a seasoned executive and an expert in business development in the global pharmaceutical industry. With more than twenty seven years of experience at Merck & Co, Inc. in leadership roles in sales, marketing and business development, Jacob negotiated a wide array of transactions, including joint ventures, divestitures, commercial collaborations, licensing, distributions and conflict resolutions. His true understanding of the business development world and his experience at Merck gained him the credibility of a person with “hands-on” experience and valuable knowledge. Jacob’s trademark ability is to quickly understand his client’s key challenges and the issues facing their business, followed by the identification and facilitation of business development initiatives that will provide effective solutions and will lead to the growth of their business. Jacob holds a bachelor’s degree in Economics and a Master of Business Administration.
Meir Menachem has held a number of senior positions in blue chip companies in more than 20-year career in Strauss Group, Kardan Group, LR Group and Delek Group, gaining considerable global Financing and Managing experience in the highly competitive and commercial environment of several business sectors. Mr. Menachem has extensive experience as board member in wide range of different organizations. Mr. Menachem received a BA in Economics and Accounting in 1992, and an MBA in Finance in 1995, both from Bar-Ilan University. Mr. Menachem is a certified public accountant (CPA) since 1994.